Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus

Shimabukuro, Michio; Higa, Mariko; Tanaka, Hiroaki; Shimabukuro, Takeshi; Yamakawa, Ken; Masuzaki, Hiroaki

doi:10.1111/j.1464-5491.2011.03240.x

Cited by 15 publications

(9 citation statements)

References 28 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 In a post hoc analysis of the Treating to New Targets study, 40 HDL-C levels during statin treatment were inversely related to the risk of cardiovascular events, even among patients with LDL-C levels , 70 mg/dL. Giving a major increase of HDL-C 35 and of apolipoprotein A1, 33 pitavastatin has a further positive effect on reducing coronary atherosclerosis. This was confirmed by Maruyama et al that observed that, despite giving a similar reduction of LDL-C, pitavastatin resulted superior to atorvastatin in reducing major adverse cardiac events, due to their differing HDL-C raising ability.…”

Section: Discussionmentioning

confidence: 96%

“…[24][25][26][27] Compared to other previously commercialized statins, pitavastatin proved to be as effective as atorvastatin in terms of the proportions of patients achieving the LDL-C goal, reductions in LDL-C, TC, and Tg, [26][27][28][29][30][31][32][33][34] but to be inferior to rosuvastatin in lowering LDL-C, and hs-CRP in patients with type 2 diabetes mellitus, 38 placing between atorvastatin and rosuvastatin in terms of effectiveness (Table 3). Moreover, compared to other statins, pitavastatin treatment was also associated with a significant greater increase in HDL-C levels ( Table 3).…”

Section: Discussionmentioning

confidence: 99%

“…33 As compared with baseline, serum levels of TC, LDL-C, non-HDL-C and LDL-C/HDL-C ratio were decreased after 1, 3, and 6 months of treatment in the atorvastatin and pitavastatin groups. Serum levels of Tg were decreased after 1, 3, and 6 months of treatment with atorvastatin and after 3 months of treatment with pitavastatin.…”

Section: Pitavastatin Compared To Other Statins Pitavastatin Vs Atormentioning

confidence: 93%

See 2 more Smart Citations

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Derosa¹,

Maffioli²

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

The progression of atherosclerosis and thus risk of cardiovascular disease is influenced by a variety of risk factors, including high levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C). Lowering the serum cholesterol level with diet or drug therapy slows the progression of angiographically documented coronary atherosclerosis in patients with arterial bypass grafts. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and LDL-C. We conducted a review analyzing clinical efficacy and safety of pitavastatin, the latest statin to be commercialized, including the most important studies about pitavastatin published in the last ten years. Pitavastatin proved to be as effective as atorvastatin, and a little inferior to rosuvastatin in improving lipid profile, it also proved to be safe and well tolerated. Because of its positive pleiotropic effects on coronary plaque volume and fibro-fatty composition, pitavastatin could be a valid option for the treatment of hypercholesterolemia and combined dyslipidemia.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Pitavastatin Compared To Other Statins Pitavastatin Vs Atormentioning

confidence: 93%

See 1 more Smart Citation

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Derosa¹,

Maffioli²

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

show abstract

“…In a study of stable CAD patients with chronic total occlusion with type 2 diabetes mellitus, Shen et al found LDL-C and non HDL-C as predictors for poor collateral development [37]. We did not include diabetic patients in our study group since in DM patients HDL-C is low and LDL-C and TG-rich lipoproteins are high [38,39]. There are no studies investigating the relationship between non-HDL-C and CCC.…”

Section: Discussionmentioning

confidence: 99%

The relationship between non-HDL cholesterol and coronary collateral circulation

Yıldırım¹,

Se²,

Argan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Non high density lipoprotein cholesterol (non HDL-C) covers all aterojenic lipoproteins and correlates with C reactive protein (CRP) which is reliable marker of inflammation. CRP is related to poor angiographic coronary collateral circulation (CCC). We aimed to show whether non HDL-C is associated with CCC.Methods Patients who underwent coronary angiography for stable coronary artery disease and at least one epicardial coronary artery occluded in the proximal or middle region were included in the study. Accrording to the Rentrop scoring system Rentrop 0 and 1 were considered to be poor CCC, and Rentrop 2 and 3 were considered to be good CCC. Non-HDL-C was calculated by subtracting HDL-C from total cholesterol (TC).Results 84 patients were included in the study. While 44 patients (52%) had good CCC, 40 patients (48%) had poor CCC. TC was found to be higher in the poor CCC group than in the good CCC group (224.3 ± 35.6 vs 179.2 ± 25.5 p = 0.000). HDL-C levels were found to be lower in the poor CCC group than in the good CCC group (37.3 ± 9.8 vs 44.1 ± 8.6 p = 0.001). Non-HDL-C cholesterol levels were higher in the group with poor CCC (185.7 ± 39.2 vs 132.8 ± 28.1 p = 0.000). CRP levels were found to be higher in the poor CCC group (3.73 ± 2.5 vs 1.67 ± 1.4 p = 0,000).Conclusion Non-HDL-C is independent predictors of poor CCC.

show abstract

“…97 Newer statins such as pitavastatin have been studied in both type 2 diabetes and metabolic syndrome, with excellent efficacy. 77,142 In addition, the efficacy and safety of pitavastatin have been studied in elderly patients in Phase III studies. 69,143 As a result of its structure and metabolism, pitavastatin could possibly be better tolerated than other statins in these populations who are frequently on polypharmacy drug regiments.…”

Section: Future Of Dyslipidemia Treatment In Special Populationsmentioning

confidence: 99%

Balancing Efficacy and Tolerability Issues with Statin Therapy— Considerations for the Use of Pitavastatin in Special Patient Populations

Falko¹

2011

US Endocrinology

View full text Add to dashboard Cite

One of the main objectives of cardiovascular care is to control elevated low-density lipoprotein cholesterol (LDL-C). Statins are the mainstay for managing LDL-C with proven high efficacy and satisfactory safety profiles. However, the most known side effects are muscle symptoms, which are particularly common in individuals who often have co-existing conditions and are taking multiple medications. The latest statin that has become available, pitavastatin, is not known to cause cytochrome P450-mediated drug–drug interactions, making it an ideal statin for individuals at a high risk for side effects. Pitavastatin will be particularly beneficial in treating patients with mixed dyslipidemia, as it is effective in reducing triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). Pitavastatin has an established history of use, and has a safety and adverse event profile similar to that of other existing statins. Individuals at high risk from side effects with statins include older people (>65 years), individuals with diabetes, kidney disease, or metabolic syndrome and individuals taking multiple medications. South Asian populations that have migrated to Western countries are at particularly high risk for cardiovascular disease, and this population also has an increased risk for statin-related side effects. This article will summarize the factors that place individuals at high risk for dyslipidemia, treatment of high risk populations with statins, and the issues associated with treating high risk populations with statins. The benefits of treating these individuals with pitavastatin will be reviewed, as well as alternative forms of therapy.

show abstract

Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus

Cited by 15 publications

References 28 publications

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

The relationship between non-HDL cholesterol and coronary collateral circulation

Balancing Efficacy and Tolerability Issues with Statin Therapy— Considerations for the Use of Pitavastatin in Special Patient Populations

Contact Info

Product

Resources

About